Tipranavir [clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f]
eligibility for clinicaltrials:NCT00397787 [clinicaltrials_resource:44f7445b33573724f39d2c3350c2edd2]eligibility for clinicaltrials:NCT00378911 [clinicaltrials_resource:90e2573b962fa7b00d8bc3d81c673d4b]eligibility for clinicaltrials:NCT00906360 [clinicaltrials_resource:ab102d1f180ab3114d9eef4e4cd8cffd]eligibility for clinicaltrials:NCT00387920 [clinicaltrials_resource:ae648621e7eda92397728786d3a31e65]eligibility for clinicaltrials:NCT00398112 [clinicaltrials_resource:baa879f991df91a619bf63a4eb76ddf8]
inclusion criteria [clinicaltrials_vocabulary:inclusion-criteria]
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals [clinicaltrials:NCT00034866]clinicaltrials:NCT00054717Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients [clinicaltrials:NCT00056641]Tipranavir in Patients With Progressive, Systemic HIV-1 Disease Who Have Failed or Are Intolerant to Currently Approved Treatments for HIV Infection [clinicaltrials:NCT00062660]clinicaltrials:NCT00076999Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection [clinicaltrials:NCT00097799]clinicaltrials:NCT00144170Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options [clinicaltrials:NCT00144287]clinicaltrials:NCT001463283 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study [clinicaltrials:NCT00275444]Study to Determine the Pharmacokinetic Behavior of Antiretroviral Drugs in Patients Infected by HIV [clinicaltrials:NCT00307502]Pharmacokinetic (PK) Study of Single-dose Rosuvastatin and Tipranavir/Ritonavir in Healthy Subjects [clinicaltrials:NCT00344123]Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together [clinicaltrials:NCT00352066]clinicaltrials:NCT00440271clinicaltrials:NCT00486330Comparison of TPV/r to DRV/r in Triple Class Experienced Patient With Resistance to > 1 PI [clinicaltrials:NCT00517192]Tipranavir/Ritonavir Low Dose Pharmacokinetics in Treatment Naive Patients [clinicaltrials:NCT00530920]Observational Non-interventional Study (Anwendungsbeobachtung) With Aptivus® (Tipranavir) in HIV-infected Patients. [clinicaltrials:NCT00531206]Clinical Trial to Assess the Security of the Dose Reduction of Ritonavir in HIV-Infected Patients in Treatment With Tipranavir/Ritonavir 500/200 mg Every 12 Hours [clinicaltrials:NCT00607958]An Open Label Safety Study of Tipranavir Co-administered With Low-dose Ritonavir in Patients With Advanced HIV-1 Infection and Limited Treatment Options. [clinicaltrials:NCT00933205]clinicaltrials:NCT00976950Drug Interaction Study Between GSK1349572 and Tipranavir/Ritonavir in Healthy Volunteers [clinicaltrials:NCT01068925]Pharmacokinetic Interaction Study of Steady-state Tipranavir/Ritonavir (TPV/r) With Single-dose Valaciclovir (VAL) in Healthy Volunteers [clinicaltrials:NCT02226978]Effects of Steady-state Efavirenz 600 mg QD (Sustiva®) on Tipranavir Concentration at Steady-state in Healthy Adult Volunteers [clinicaltrials:NCT02226991]Effect of Steady State TPV/r on Intracellular Concentrations of Zidovudine and Carbovir for Patients With HIV [clinicaltrials:NCT02229760]Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients [clinicaltrials:NCT02238314]Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients [clinicaltrials:NCT02239835]Effects of Tipranavir (With Ritonavir) Capsule and Liquid Formulation on Cytochrome P450 and P-glycoprotein Activity in Healthy Volunteers [clinicaltrials:NCT02243553]Bioequivalence of Two Different Oral Solutions Tipranavir Administered in Combination With Ritonavir to Healthy Volunteers [clinicaltrials:NCT02244190]Pharmacokinetics of Atorvastatin With Tipranavir/Ritonavir and the Effect of Antacid on the Pharmacokinetics of Single-Dose Tipranavir/Ritonavir in Healthy Volunteers [clinicaltrials:NCT02245269]Effect of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Norethindrone-Ethinyl Estradiol in Healthy Female Adult Volunteers [clinicaltrials:NCT02245438]Study of Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Methadone Administered in Healthy Volunteers [clinicaltrials:NCT02245451]Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir [clinicaltrials:NCT02249130]Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers [clinicaltrials:NCT02249416]The Pharmacodynamic/Pharmacokinetic Interaction of Tipranavir and Ritonavir With Loperamide in Healthy Volunteers [clinicaltrials:NCT02251119]Effects of Tipranavir (TPV) and Ritonavir (RTV) on the Pharmacokinetic Characteristics of Tenofovir Disoproxil Fumarate in Healthy Volunteers [clinicaltrials:NCT02251145]Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects [clinicaltrials:NCT02251158]Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers [clinicaltrials:NCT02251171]Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects [clinicaltrials:NCT02251223]Effects of Single-dose and Steady-state TPV/r on the Steady-state Pharmacokinetics of Clarithromycin and a Preliminary Assessment of the Effects of a Standard High-fat Test Meal on the Steady-state Pharmacokinetics of Tipranavir [clinicaltrials:NCT02251769]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
Tipranavir [clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f]
Bio2RDF identifier
0257284ce5995d22e129676eccd3df2f
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f
identifier
clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f
title
Tipranavir
@en
type
label
Tipranavir [clinicaltrials_resource:0257284ce5995d22e129676eccd3df2f]
@en